ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v10i2.654ppharm-244Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCASE REPORTОПЫТ ПРИМЕНЕНИЯ МЕТОТРЕКСАТА У БОЛЬНОЙ С РАННИМ ОЛИГОАРТИКУЛЯРНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМEXPERIENCE OF USING METHOTREXATE IN A PATIENT WITH EARLY OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITISСлепцоваТ. В.SleptsovaT. V.alekatya@ya.ruАлексееваЕ. И.AlexeevaE. I.

доктор медицинских наук, профессор, заведующая отделением ревматологии НЦЗД РАМН

alekatya@ya.ruБзароваТ. М.BzarovaT. M.alekatya@ya.ruИсаеваК. Б.IsaevaK. B.alekatya@ya.ruМитенкоЕ. В.MitenkoE. V.alekatya@ya.ruНаучный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian FederationНаучный центр здоровья детей РАМН, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian FederationRussian Federation201301042013102Педиатрическая фармакология121126Copyright © Слепцова Т.В., Алексеева Е.И., Бзарова Т.М., Исаева К.Б., Митенко Е.В., 20132013Слепцова Т.В., Алексеева Е.И., Бзарова Т.М., Исаева К.Б., Митенко Е.В.Sleptsova T.V., Alexeeva E.I., Bzarova T.M., Isaeva K.B., Mitenko E.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/244

В статье представлен случай тяжелого течения олигоартикулярного ювенильного идиопатического артрита с развитием контрактуры и деструктивных изменений в суставах. Описано успешное применение метотрексата в дозе 15 мг/м2 поверхности тела в нед подкожно у пациентки с ранним артритом (длительностью болезни менее двух лет): через 6 мес от начала терапии у ребенка купировались островоспалительные изменения в суставах, артралгии, утренняя скованность; через 12 мес полностью восстановился объем движений в пораженных суставах. Фаза неактивной болезни и ремиссия были зарегистрированы через 6 и 12 мес, соответственно. Ремиссия сохраняется в течение 12 мес.

The article describes a case with a severe course of oligoarticular juvenile idiopathic arthritis with the development of contracture and destructive articular alterations. The successful use of methotrexate (15mg/m2 of body surface per week, subcutaneously) in a child with early arthritis (disease duration – less than 2 years) is described: 6 months after the therapy had started, acute inflammatory articular alterations, arthralgiae, morning stiffness terminated; in 12 months the range of motions in the affected joints recovered completely. The inactive disease phase and remission were registered in 6 and 12 months, accordingly. The remission has continued for 12 months.

детиювенильный идиопатический артритметотрексатподкожное введениеchildrenjuvenile idiopathic arthritismethotrexatesubcutaneous introductionReferencesCassidy J., Petty R., Laxer R. M., Lindsley C. B. Texbook of paediatric rheumatology, 6th еd. Philadelphia: Elsevier Saunders. 2010. 794 р.Cassidy J., Petty R., Laxer R. M., Lindsley C. B. Texbook of paediatric rheumatology, 6th еd. Philadelphia: Elsevier Saunders. 2010. 794 р.Алексеева Е. И., Литвицкий П. Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. М.: Веди. 2007. 359 с.Alekseeva E.I., Litvitskii P.F. Revmatoidnyi artrit. Etiologiya, patogenez. Klinika. Algoritmy diagnostiki i lecheniya [Rheumatoid Arthritis. Etiology, Pathogenesis. Clinic. Algorithms for Diagnosis and Treatment]. Moscow, Vedi, 2007. 359 p.Kroot E. J. A., van Leeuwen M. A., van Rijswijk M. H. et al. No increased mortality in patient with rheumatoid arthritis: up to 10 years of follow–up from disease onset. Ann Rheum Dis. 2000; 59: 954–958.Kroot E. J. A., van Leeuwen M. A., van Rijswijk M. H. et al. No increased mortality in patient with rheumatoid arthritis: up toКлинические рекомендации. Ревматология. Под ред. Е. Л. Насонова. М.: ГЭОТАР-Медиа. 2005. С. 25–71, 120–140.years of follow–up from disease onset. Ann Rheum Dis. 2000; 59: 954–958.Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., Dewitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care & Research. 2011; 63 (4): 465–482.Klinicheskie rekomendatsii. Revmatologiya. Pod red. E.L. Nasonova [Clinical Recommendations. Rheumatology. Edited by E.L.Nasonov]. Moscow, GEOTAR-Media, 2005. pp. 25–71, 120–140.Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opin Drug Saf. 2003; 2 (4): 347–365.Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., Dewitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care & Research. 2011; 63 (4): 465–482.Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opin Drug Saf. 2003; 2 (4): 347–365.Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis. Therapy. 1999; 81: 766–772.Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294 (13): 1671–1684.Tynjala P., Vahasalo P., Tarkiainen M., Kroger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011. Р. 70.Yokota S. Classification and treatment strategy for juvenile idiopathic arthritis. Therapy. 1999; 81: 766–772.Visvanathan S., Wagner C., Marini J. C., Loveд D. J., Martini A., Petty R., Cuttica R., Woo P., Espada G., Gattorno M., Apaz M. T., Baildam E., Fasth A., Gerloni1 V., Lahdenne P., Quartier P., Saurenmann R., Travers S., Mendelsohn A., Xu S., Giannini E. H., Ruperto N. For the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatric Rheumatology. 2010; 8: 24.Tynjala P., Vahasalo P., Tarkiainen M., Kroger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011. Р. 70.Alarcon G. S. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In arthritis and allied conditions. A Text book of rheumatology, 13th Edition. Ed. W. J. Koopman. Baltimore, Philadelphia, London: Williams & Wilkins. 1997; 1: 679–98.Visvanathan S., Wagner C., Marini J. C., Loveд D. J., Martini A., Petty R., Cuttica R., Woo P., Espada G., Gattorno M., Apaz M. T., Baildam E., Fasth A., Gerloni1 V., Lahdenne P., Quartier P.,Cronstein B. N. The mechanism of action of methotrexate. Rheum Dis Clin North Amer. 1997; 23: 739–755.Saurenmann R., Travers S., Mendelsohn A., Xu S., Giannini E. H., Ruperto N. For the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatric Rheumatology. 2010; 8: 24.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.Alarcon G. S. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In arthritis and allied conditions. A Text book of rheumatology, 13th Edition. Ed. W. J. Koopman. Baltimore, Philadelphia, London: Williams & Wilkins. 1997; 1: 679–98.Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J Pediatr. 1998; 133: 179–180.Cronstein B. N. The mechanism of action of methotrexate. Rheum Dis Clin North Amer. 1997; 23: 739–755.Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012; 64 (9): 1349–56.Tambic-Bukovac L., Malcic I., Prohic A. Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis. Rheumatism. 2002; 49 (1): 20–24.Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992; 326: 1043–1049.Cassidy J. T. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J Pediatr. 1998; 133: 179–180.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr Rheum. 2000; 43 (8): 1849–1857.Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012; 64 (9): 1349–56.Silverman E., Mouy R., Spiegel L. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005; 352: 1655–1666.Giannini E. H., Brewer E. J., Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992; 326: 1043–1049.Кузьмина Н. Н., Брюэр Э., Шайков А. В. и др. Клинич. ревматол. 1994; 1: 3–7.Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr Rheum. 2000; 43 (8): 1849–1857.Albertioni F., Flato B., Seideman P. et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol. 1995; 47 (6): 507–511.Silverman E., Mouy R., Spiegel L. et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005; 352: 1655–1666.Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191–2201.Kuz'mina N.N., Bryuer E., Shaikov A.V. et al. Klinich. revmatol. – Clinical rheumatology. 1994; 1: 3–7.Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009; 27 (6): 1047–1053.Albertioni F., Flato B., Seideman P. et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol. 1995; 47 (6): 507–511.Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004; 31 (1): 179–182.Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191–2201.Kugathasan S., Newman A. J., Dahms B. B. et al. Liver biopsy findings liver in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr. 1996; 128 (1): 149–151.Tukova J., Chladek J., Nemcova D. et al. Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009; 27 (6): 1047–1053.Cron R. Q., Sherry D. D., Wallace C. A. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr. 1998; 132 (5): 901–902.Alsufyani K., Ortiz-Alvarez O., Cabral D. A. et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004; 31 (1): 179–182.Wallace C. A., Giannini E. H., Huang В., Itert L., Ruperto N. Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) (2011), American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011; 63: 929–936. Doi: 10.1002/acr.20497.Kugathasan S., Newman A. J., Dahms B. B. et al. Liver biopsy findings liver in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J Pediatr. 1996; 128 (1): 149–151.Баранов А.А., Насонов Е.Л., Алексеева Е.И., Эрдес Ш.Ф., Ильин А.Г. Состояние специализированной ревматологической помощи детям и взрослым в Российской Федерации. Проект Федеральной целевой программы «Ревматические болезни 2008-2012 гг.» (По материалам доклада на заседании Президиума РАМН, 17 января 2007 г.) Вопросы современной педиатрии. 2007; 6 (1): 6–8.Cron R. Q., Sherry D. D., Wallace C. A. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr. 1998; 132 (5): 901–902.Wallace C. A., Giannini E. H., Huang В., Itert L., Ruperto N. Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) (2011), American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011; 63: 929–936. Doi: 10.1002/acr.20497.Wallace C. A., Giannini E. H., Huang В., Itert L., Ruperto N. Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) (2011), American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res. 2011; 63: 929–936. Doi: 10.1002/acr.20497.Baranov A.A., Nasonov E.L., Alexeeva E.I., Erdes Sh.F., Il'in A.G. Voprosy sovremennoi pediatrii – Current pediatrics. 2007; 6 (1): 6–8.Baranov A.A., Nasonov E.L., Alexeeva E.I., Erdes Sh.F., Il'in A.G. Voprosy sovremennoi pediatrii – Current pediatrics. 2007; 6 (1): 6–8.

The authors declare that there are no conflicts of interest present.